SCHEMBL6094748

SCHEMBL6094748

FC(F)(F)c1cccc(N2[CH]CNCC2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.63
ALDH1A1 P00352 3/20 0.63
HTR3E A5X5Y0 1/20 0.63
HTR3B O95264 1/20 0.63
HTR1D P28221 1/20 0.63
HTR3A P46098 1/20 0.63
HTR3D Q70Z44 1/20 0.63
HTR3C Q8WXA8 1/20 0.63
SIGMAR1 Q99720 1/20 0.63
MAPT P10636 2/20 0.61
THRB P10828 1/20 0.61
HTR2A P28223 1/20 0.46
HTR2B P41595 1/20 0.46
ADRB1 P08588 2/20 0.45
ALOX5 P09917 2/20 0.45
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
IDH2 P48735 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231692 0.78 ALDH1A1 (1.00) HTR2CALDH1A1HTR3EHTR3BHTR1D
SCHEMBL6094745 0.78 ALDH1A1 (1.00) HTR2CALDH1A1HTR3EHTR3BHTR1D
Hydrochloric Acid SCHEMBL720648 0.76 THRB (1.00) HTR2CALDH1A1HTR3EHTR3BHTR1D
SCHEMBL28131941 0.76 ALDH1A1 (0.51) HTR2CALDH1A1HTR3EHTR3BHTR1D
SCHEMBL4885913 0.76 HTR2C (0.60) HTR2CALDH1A1HTR3EHTR3BHTR3A
Hydrochloric Acid SCHEMBL12818335 0.76 THRB (1.00) HTR2CALDH1A1HTR3EHTR3BHTR1D
Bromide SCHEMBL9146763 0.76 ALDH1A1 (0.97) HTR2CALDH1A1HTR3EHTR3BHTR1D
Piperazine SCHEMBL28225297 0.75 THRB (0.97) HTR2CALDH1A1HTR3EHTR3BHTR1D
SCHEMBL739058 0.75 SIGMAR1 (0.52) HTR2CALDH1A1HTR3EHTR3BHTR3A
SCHEMBL3482603 0.74 ADRB1 (0.62) HTR2CHTR3EHTR3BHTR1DHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030150-B2 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2006-04-18 US claimed
US-20030119754-A1 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2003-06-26 US claimed
WO-2002092575-A1 BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF TRIMERIS, INC. (US) 2002-11-21 WO claimed
US-20060142365-A1 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2006-06-29 US disclosed
US-7030150-B2 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2006-04-18 US disclosed
US-20030119754-A1 Benzimidazole compounds and antiviral uses thereof TRIMERIS, INC. 2003-06-26 US disclosed
WO-2002092575-A1 BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF TRIMERIS, INC. (US) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142365-A1 Benzimidazole compounds and antiviral uses thereof MAVS, ZC3HAV1, TIMM13 HTR2C 3781/4885ALDH1A1 1618/4885HTR3E 1875/4885
US-20030119754-A1 Benzimidazole compounds and antiviral uses thereof MAVS, ZC3HAV1, TIMM13 HTR2C 3781/4885ALDH1A1 1618/4885HTR3E 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.